{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:54:36Z","timestamp":1782878076691,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,4]]},"DOI":"10.7759\/cureus.48258","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T12:24:52Z","timestamp":1699100692000},"source":"Crossref","is-referenced-by-count":1,"title":["Safety and Effectiveness of Tofacitinib in Treating Polyarticular Course Juvenile Idiopathic Arthritis"],"prefix":"10.7759","author":[{"given":"Nicholas T","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camryn  L","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raegan  B","family":"Abadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B","family":"Bratton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmilee J","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyton","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Rieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Tirumala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00332-8","article-title":"Juvenile idiopathic arthritis","volume":"8","author":"Martini A","year":"2022","unstructured":"Martini A, Lovell DJ, Albani S, Brunner HI, Hyrich KL, Thompson SD, Ruperto N. Juvenile idiopathic arthritis. Nat Rev Dis Primers. 2022, 8:5. 10.1038\/s41572-021-00332-8","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","unstructured":"Polyarticular juvenile idiopathic arthritis. Clinical manifestations, diagnosis, and complications. (2023). Accessed: March 19, 2023: https:\/\/www.uptodate.com\/contents\/polyarticular-juvenile-idiopathic-arthritis-clinical-manifestations-diagnosis-and-c...."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000206","article-title":"Advances in the treatment of polyarticular juvenile idiopathic arthritis","volume":"27","author":"Webb K","year":"2015","unstructured":"Webb K, Wedderburn LR. Advances in the treatment of polyarticular juvenile idiopathic arthritis. Curr Opin Rheumatol. 2015, 27:505-510. 10.1097\/BOR.0000000000000206","journal-title":"Curr Opin Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S53168","article-title":"Polyarticular juvenile idiopathic arthritis - epidemiology and management approaches","volume":"6","author":"Oberle EJ","year":"2014","unstructured":"Oberle EJ, Harris JG, Verbsky JW. Polyarticular juvenile idiopathic arthritis - epidemiology and management approaches. Clin Epidemiol. 2014, 6:379-393. 10.2147\/CLEP.S53168","journal-title":"Clin Epidemiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00610-5","article-title":"Publisher correction: biological classification of childhood arthritis: roadmap to a molecular nomenclature","volume":"17","author":"Nigrovic PA","year":"2021","unstructured":"Nigrovic PA, Colbert RA, Holers VM, et al.. Publisher correction: biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat Rev Rheumatol. 2021, 17:306. 10.1038\/s41584-021-00610-5","journal-title":"Nat Rev Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1542\/peds.109.1.109","article-title":"Current treatment of juvenile rheumatoid arthritis","volume":"109","author":"Ilowite NT","year":"2002","unstructured":"Ilowite NT. Current treatment of juvenile rheumatoid arthritis. Pediatrics. 2002, 109:109-115. 10.1542\/peds.109.1.109","journal-title":"Pediatrics"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23870","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis","volume":"71","author":"Ringold S","year":"2019","unstructured":"Ringold S, Angeles-Han ST, Beukelman T, et al.. 2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res (Hoboken). 2019, 71:717-734. 10.1002\/acr.23870","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102226","article-title":"Therapeutic strategies for treating juvenile idiopathic arthritis","volume":"64","author":"Mannion ML","year":"2022","unstructured":"Mannion ML, Cron RQ. Therapeutic strategies for treating juvenile idiopathic arthritis. Curr Opin Pharmacol. 2022, 64:102226. 10.1016\/j.coph.2022.102226","journal-title":"Curr Opin Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-019-0669-6","article-title":"Managing risks with biologics","volume":"21","author":"Click B","year":"2019","unstructured":"Click B, Regueiro M. Managing risks with biologics. Curr Gastroenterol Rep. 2019, 21:1. 10.1007\/s11894-019-0669-6","journal-title":"Curr Gastroenterol Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4805-413","article-title":"Tofacitinib","volume":"48","author":"Cada DJ","year":"2013","unstructured":"Cada DJ, Demaris K, Levien TL, Baker DE. Tofacitinib. Hosp Pharm. 2013, 48:413-424. 10.1310\/hpj4805-413","journal-title":"Hosp Pharm"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/psb.1635","article-title":"Janus kinase inhibitors for autoimmune disorders","volume":"28","author":"Chaplin S","year":"2017","unstructured":"Chaplin S. Janus kinase inhibitors for autoimmune disorders. Prescriber. 2017, 28:33-37. 10.1002\/psb.1635","journal-title":"Prescriber"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0835-9","article-title":"Tofacitinib: a review in rheumatoid arthritis","volume":"77","author":"Dhillon S","year":"2017","unstructured":"Dhillon S. Tofacitinib: a review in rheumatoid arthritis. Drugs. 2017, 77:1987-2001. 10.1007\/s40265-017-0835-9","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.734","article-title":"Extended-release once-daily formulation of tofacitinib: evaluation of pharmacokinetics compared with immediate-release tofacitinib and impact of food","volume":"56","author":"Lamba M","year":"2016","unstructured":"Lamba M, Wang R, Fletcher T, Alvey C, Kushner J 4th, Stock TC. Extended-release once-daily formulation of tofacitinib: evaluation of pharmacokinetics compared with immediate-release tofacitinib and impact of food. J Clin Pharmacol. 2016, 56:1362-1371. 10.1002\/jcph.734","journal-title":"J Clin Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2008.11.017","article-title":"Extrudable core system: development of a single-layer osmotic controlled-release tablet","volume":"134","author":"Waterman KC","year":"2009","unstructured":"Waterman KC, MacDonald BC, Roy MC. Extrudable core system: development of a single-layer osmotic controlled-release tablet. J Control Release. 2009, 134:201-206. 10.1016\/j.jconrel.2008.11.017","journal-title":"J Control Release"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-eular.1521","article-title":"Pharmacokinetics, bioavailability and safety of a modified-release once-daily formulation of tofacitinib in healthy volunteers","volume":"73","author":"Lamba M","year":"2014","unstructured":"Lamba M, Wang R, Fletcher T, et al.. Pharmacokinetics, bioavailability and safety of a modified-release once-daily formulation of tofacitinib in healthy volunteers. Ann Rheum Dis. 2014, 73:228-232. 10.1136\/annrheumdis-2014-eular.1521","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12080714","article-title":"Slower elimination of tofacitinib in acute renal failure rat models: contribution of hepatic metabolism and renal excretion","volume":"12","author":"Bae SH","year":"2020","unstructured":"Bae SH, Chang SY, Kim SH. Slower elimination of tofacitinib in acute renal failure rat models: contribution of hepatic metabolism and renal excretion. Pharmaceutics. 2020, 12:10.3390\/pharmaceutics12080714","journal-title":"Pharmaceutics"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00938-z","article-title":"Critical assessment of pharmacokinetic drug-drug interaction potential of tofacitinib, baricitinib and upadacitinib, the three approved janus kinase inhibitors for rheumatoid arthritis treatment","volume":"43","author":"Veeravalli V","year":"2020","unstructured":"Veeravalli V, Dash RP, Thomas JA, Babu RJ, Madgula LM, Srinivas NR. Critical assessment of pharmacokinetic drug-drug interaction potential of tofacitinib, baricitinib and upadacitinib, the three approved janus kinase inhibitors for rheumatoid arthritis treatment. Drug Saf. 2020, 43:711-725. 10.1007\/s40264-020-00938-z","journal-title":"Drug Saf"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5\u2009years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt J","year":"2019","unstructured":"Wollenhaupt J, Lee EB, Curtis JR, et al.. Safety and efficacy of tofacitinib for up to 9.5\u2009years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019, 21:89. 10.1186\/s13075-019-1866-2","journal-title":"Arthritis Res Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen SB","year":"2020","unstructured":"Cohen SB, Tanaka Y, Mariette X, et al.. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020, 6:10.1136\/rmdopen-2020-001395","journal-title":"RMD Open"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5\u2005years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen SB","year":"2017","unstructured":"Cohen SB, Tanaka Y, Mariette X, et al.. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5\u2005years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017, 76:1253-1262. 10.1136\/annrheumdis-2016-210457","journal-title":"Ann Rheum Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14324","article-title":"Efficacy and safety of tofacitinib in the treatment of refractory cases of polyarticular course juvenile idiopathic arthritis: a\u00a0study from Bangladesh","volume":"25","author":"Rahman MM","year":"2022","unstructured":"Rahman MM, Laila K, Rahman SA. Efficacy and safety of tofacitinib in the treatment of refractory cases of polyarticular course juvenile idiopathic arthritis: a\u00a0study from Bangladesh. Int J Rheum Dis. 2022, 25:678-684. 10.1111\/1756-185X.14324","journal-title":"Int J Rheum Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200154","article-title":"Absence of association between abatacept exposure and initial infection in patients with juvenile idiopathic arthritis","volume":"48","author":"Ruperto N","year":"2021","unstructured":"Ruperto N, Brunner HI, Tzaribachev N, et al.. Absence of association between abatacept exposure and initial infection in patients with juvenile idiopathic arthritis. J Rheumatol. 2021, 48:1073-1081. 10.3899\/jrheum.200154","journal-title":"J Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.143","article-title":"The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor","volume":"3","author":"Lawendy N","year":"2014","unstructured":"Lawendy N, Lamba M, Chan G, Wang R, Alvey CW, Krishnaswami S. The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor. Clin Pharmacol Drug Dev. 2014, 3:421-427. 10.1002\/cpdd.143","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto N","year":"2021","unstructured":"Ruperto N, Brunner HI, Synoverska O, et al.. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet. 2021, 398:1984-1996. 10.1016\/S0140-6736(21)01255-1","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-2845","article-title":"Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis","volume":"143","author":"Huang Z","year":"2019","unstructured":"Huang Z, Lee PY, Yao X, Zheng S, Li T. Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis. Pediatrics. 2019, 143:10.1542\/peds.2018-2845","journal-title":"Pediatrics"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/188618-safety-and-effectiveness-of-tofacitinib-in-treating-polyarticular-course-juvenile-idiopathic-arthritis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:02Z","timestamp":1707509402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/188618-safety-and-effectiveness-of-tofacitinib-in-treating-polyarticular-course-juvenile-idiopathic-arthritis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,4]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.48258","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,4]]}}}